NYSE:BIOLife Sciences
Bio-Rad’s Restructuring and Digital PCR Momentum Might Change The Case For Investing In BIO
In early August 2026, Bio-Rad Laboratories reported second-quarter 2026 results showing sales of US$651.0 million, higher net income of US$371.4 million, and reaffirmed full-year non-GAAP guidance while outlining expectations for flat third-quarter revenue and a mid-single-digit percentage ramp into the fourth quarter.
The company also highlighted strong digital PCR growth above 20%, a return to growth in clinical diagnostics, and a new restructuring program targeting US$30 million to US$35...